Pyxis Oncology (PYXS) Gains from Sales and Divestitures (2021 - 2022)

Pyxis Oncology (PYXS) reported Gains from Sales and Divestitures of $196164.0 for Q2 2022, up 94.4% quarter-over-quarter from $100908.0 in Q1 2022.

Pyxis Oncology (PYXS) Gains from Sales and Divestitures (2021 - 2022) Analysis & Trends

Pyxis Oncology (PYXS) has 2 years of Gains from Sales and Divestitures data on file, last reported at $196164.0 in Q2 2022.

Gains from Sales and Divestitures for Q2 2022 came in at $196164.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2022 was $196164.0 (changed N/A YoY), and the FY2021 annual result was $306998.0, changed N/A from the prior year.
Gains from Sales and Divestitures climbed to $196164.0 in Q2 2022 per PYXS's latest filing, from $100908.0 in the prior quarter.
Over five years, Gains from Sales and Divestitures peaked at $333888.0 in Q3 2021 and troughed at $100908.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Pyxis Oncology	125.84 Mn	108.95 Mn	8.65 Mn

Download Data